Connect with us

News

Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases

gbafNews28

Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the completion of a $100 million Series B financing led by Matrix Capital Management, with participation from Series A investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures, as well as new investor Surveyor Capital (a Citadel company).

Glycobiology is an emerging field that has long been hampered by scientific complexity and a lack of enabling technologies. However, recent technical advances have led to the recognition of its dominant role in immune regulation. It is now understood that immune cell activation and suppression is influenced by previously undetectable cell surface glycan patterns, and that pathologic glycosylation drives immune system dysfunction in a range of diseases. For example, tumors develop distinct surface patterns of sialic acid-containing glycans, or sialoglycans, which bind to immune checkpoint receptors called Siglecs, resulting in suppression of all the critical innate and adaptive immune cells responsible for tumor destruction. The pan-immune aspect of sialoglycan-mediated immune evasion suggests that targeting this axis could be a very effective approach to cancer immunotherapy in patients who are resistant to existing therapies. Conventional therapeutic approaches are not feasible, however, due to substantial redundancy in the biology, as there are over a dozen Siglec receptors and many sialoglycan ligands that bind to each of them.

Palleon is advancing a suite of platform technologies that uniquely enable drug development in glyco-immunology. The company is building a robust pipeline of first-in-class drug candidates to address several devastating diseases. Palleons EAGLE platform employs a novel strategy of enzymatic sialoglycan degradation which overcomes intractable biological redundancy and enables a uniquely pan-immune anti-tumor response to address patient populations who are resistant to first generation immuno-oncology drugs. Palleons HYDRA translational platform characterizes cancer patients by their tumor surface glycan profile to identify populations who have tumors that utilize this mechanism. Palleons lead program, Sialidase-Fc is an enzymatic sialoglycan degrader that will enter clinical testing in 2021 in cancer patient populations defined by an immunosuppressive tumor glycan profile. In addition, Palleon is developing a broad pipeline of drug candidates that target individual Siglecs and other glycan-sensing receptors that may have applications in inflammatory diseases such as autoimmunity and fibrosis. The Series B funding will be used to advance Palleons pipeline of drug candidates to human clinical trials.

Jim Broderick, MD, Chief Executive Officer and Founder of Palleon, commented, We are very excited to work with Matrix Capital Management as we advance our pipeline of novel therapeutics to the clinic, and we are most grateful for the continued support and commitment of our existing investors. Glycan-mediated immune regulation presents an enormous opportunity for novel therapeutics to treat a range of diseases characterized by immune system dysfunction, including cancer and inflammatory diseases. Palleon is committed to understanding and fully exploiting this mechanism of immune regulation for the benefit of patients who suffer from these deadly and debilitating conditions.

Karan Takhar, Managing Director at Matrix Capital Management, added, Palleons team of expert scientists, broadly enabling platform technologies, strong preclinical progress, and extensive intellectual property portfolio have positioned the company to be the leader in the emerging field of glycan-mediated immune regulation. We look forward to working together to develop new medicines that can meaningfully improve patients lives.

About Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. The companys proprietary platforms integrate technologies and insights from global scientific leaders in the glyco-immunology field to overcome historical scientific hurdles and create novel therapeutics for devastating diseases characterized by immune system dysfunction. Palleons lead program in oncology, an enzymatic sialoglycan degrader, is expected to enter clinical testing in 2021. The company has several other drug discovery programs underway in disease areas where glycan-mediated immune regulation plays a role, including inflammatory diseases such as autoimmunity and fibrosis. Palleon was launched in 2015. Learn more at www.palleonpharma.com.

Nichole Sarkis

Ten Bridge Communications

[email protected]

774-278-8273

News

Putnam Announces Dividend Rates for Open-End Funds

gbafNews28

The Trustees of The Putnam Funds have declared the following distributions today.

 

RECORD

PAYMENT

FUND NAME AND DISTRIBUTIONS

DATE

DATE

 

Putnam Growth Opportunities Fund “ Class A Shares (POGAX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class B Shares (POGBX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class C Shares (POGCX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class R Shares (PGORX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class Y Shares (PGOYX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class R5 Shares (PGODX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class R6 Shares (PGOEX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Multi-Cap Core Fund “ Class A Shares (PMYAX)

$0.2580 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.6580 per share total

 

Putnam Multi-Cap Core Fund “ Class B Shares (PMYBX)

$0.0370 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.4370 per share total

 

Putnam Multi-Cap Core Fund “ Class C Shares (PMYCX)

$0.0470 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.4470 per share total

 

Putnam Multi-Cap Core Fund “ Class R Shares (PMYZX)

$0.1490 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.5490 per share total

 

Putnam Multi-Cap Core Fund “ Class Y Shares (PMYYX)

$0.3210 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.7210 per share total

 

Putnam Multi-Cap Core Fund “ Class R6 Shares (PMYTX)

$0.3510 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.7510 per share total

 

Putnam Research Fund “ Class A Shares (PNRAX)

$0.2360 per share investment income

12/4/20

12/8/20

$0.1630 per share short-term capital gain

$0.4090 per share long-term capital gain

$0.8080 per share total

 

Putnam Research Fund “ Class B Shares (PRFBX)

$0.1630 per share short-term capital gain

12/4/20

12/8/20

$0.4090 per share long-term capital gain

$0.5720 per share total

 

Putnam Research Fund “ Class C Shares (PRACX)

$0.1630 per share short-term capital gain

12/4/20

12/8/20

$0.4090 per share long-term capital gain

$0.5720 per share total

 

Putnam Research Fund “ Class R Shares (PRSRX)

$0.1470 per share investment income

12/4/20

12/8/20

$0.1630 per share short-term capital gain

$0.4090 per share long-term capital gain

$0.7190 per share total

 

Putnam Research Fund “ Class Y Shares (PURYX)

$0.3130 per share investment income

12/4/20

12/8/20

$0.1630 per share short-term capital gain

$0.4090 per share long-term capital gain

$0.8850 per share total

 

Putnam Research Fund “ Class R6 Shares (PLJMX)

$0.3710 per share investment income

12/4/20

12/8/20

$0.1630 per share short-term capital gain

$0.4090 per share long-term capital gain

$0.9430 per share total

 

Putnam Small Cap Growth Fund “ Class A Shares (PNSAX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class B Shares (PNSBX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class C Shares (PNSCX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class R Shares (PSGRX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class Y Shares (PSYGX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class R6 Shares (PLKGX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Value Fund “ Class A Shares (PSLAX)

$0.1030 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class B Shares (PSLBX)

$0.0430 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class C Shares (PSLCX)

$0.0750 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class R Shares (PSCRX)

$0.0780 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class Y Shares (PYSVX)

$0.1240 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class R5 Shares (PSLRX)

$0.1330 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class R6 Shares (PSCMX)

$0.1450 per share investment income

12/4/20

12/8/20

 

Putnam Sustainable Future Fund “ Class A Shares (PMVAX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class B Shares (PMVBX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class C Shares (PMPCX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class R Shares (PMVRX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class Y Shares (PMVYX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class R6 Shares (PNOTX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Leaders Fund “ Class A Shares (PNOPX)

$0.3320 per share investment income

12/4/20

12/8/20

$0.4740 per share short-term capital gain

$7.5340 per share long-term capital gain

$8.3400 per share total

 

Putnam Sustainable Leaders Fund “ Class B Shares (PNOBX)

$0.4740 per share short-term capital gain

12/4/20

12/8/20

$7.5340 per share long-term capital gain

$8.0080 per share total

 

Putnam Sustainable Leaders Fund “ Class C Shares (PNOCX)

$0.4740 per share short-term capital gain

12/4/20

12/8/20

$7.5340 per share long-term capital gain

$8.0080 per share total

 

Putnam Sustainable Leaders Fund “ Class R Shares (PNORX)

$0.1340 per share investment income

12/4/20

12/8/20

$0.4740 per share short-term capital gain

$7.5340 per share long-term capital gain

$8.1420 per share total

 

Putnam Sustainable Leaders Fund “ Class Y Shares (PSLGX)

$0.5920 per share investment income

12/4/20

12/8/20

$0.4740 per share short-term capital gain

$7.5340 per share long-term capital gain

$8.6000 per share total

 

Putnam Sustainable Leaders Fund “ Class R6 Shares (PNOYX)

$0.6910 per share investment income

12/4/20

12/8/20

$0.4740 per share short-term capital gain

$7.5340 per share long-term capital gain

$8.6990 per share total

 

PUTNAM SHAREHOLDERS CONTACT: 1-800-225-1581

Continue Reading

News

Zane Morton to oversee DHL Global Forwarding in New Zealand and Fiji

gbafNews28

  • The logistics veteran brings four decades of DHL experience to the key role in the South Pacific

SINGAPORE – Media OutReach – 1 December 2020 – As the business in DHL Global Forwarding New Zealand and Fiji continue on its growth trajectory, the freight specialist of the Deutsche Post DHL Group officially appoints Zane Morton as Managing Director for these two countries in the South Pacific effective today. Having built an illustrious career with the Group spanning almost four decades, Morton will lead the operations in New Zealand and oversee the growth of the business in Fiji, managed by Country Manager Ray Viegas, who will report to him.

[View Image]

 

“Across his many different roles and responsibilities, Zane has proven himself to be a respected leader, who is customer-oriented in his outlook and finely attuned to developments in the logistics and freight forwarding industry. We are confident he will help our businesses in New Zealand and Fiji reach greater heights amidst the current challenging microenvironment and augment existing synergies between our operations in New Zealand and Fiji,” said Charles Kaufmann, CEO, DHL Global Forwarding North Asia South Pacific.

 

New Zealand’s exports grew 58.6% in the last decade between 2009 and 2019. DHL Global Forwarding is optimistic about the growth potential in the market and considers perishables, life sciences and healthcare, amongst others, as promising areas that the company would further develop.

 

Reporting to Kaufmann in this new role, Morton said, “I’m acutely aware that I’m taking on the role at a very interesting time. In the short term, the industry will face a massive undertaking of delivering an unprecedented volume of more than 10 billion doses of vaccines worldwide; at the same time, DHL Global Forwarding is undergoing a digital transformation with the rollout of myDHLi in accordance to the Group’s Strategy 2025 to futureproof the organization and improve operational excellence in the long term. I am excited to lead the teams in New Zealand and Fiji to take on these challenges and leverage the opportunities to bring the business to greater heights.”

 

DHL recently published a white paper on securing a stable supply chain for vaccines and medical goods during health crises and how the transport of vaccines as a highly temperature-sensitive product can be managed effectively to combat the further spread of the COVID-19 virus. The global logistics leader has been serving the life science and healthcare sector for over 20 years, shipping all sorts of pharmaceutical and medical-related products, including vaccines and therapeutics, worldwide.

 

Morton first joined DHL in New Zealand in 1983 and held various positions during his career, including Operations Management, Country Sales & Marketing Manager, Country Ocean Freight Manager and Wellington Branch Manager. In 2006, he relocated to Dubai where he was the Regional Marketing and Sales Manager for DHL Middle East and Africa for DHL Global Forwarding. He returned to New Zealand in 2011 and was appointed Head of Ocean Freight in 2012, and subsequently named Head of Sales in 2015.

 

Note to editors:

The New Zealand- Europe FTA represents an opportunity to gain better access to the bloc’s almost 500 million consumers through lower tariffs, and new multi-modal shipping options could also lead to even more savings for importers. Read more on DHL’s Logistics of Things.


DHL – The logistics company for the world

DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With about 380,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.

DHL is part of Deutsche Post DHL Group. The Group generated revenues of more than 63 billion euros in 2019. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. Deutsche Post DHL Group aims to achieve zero-emissions logistics by 2050.

Continue Reading

News

Blake Dair Announces New Managing Partner

gbafNews28

SINGAPORE – Media OutReach – 1 December 2020 – Blake Dair Consulting Pte Ltd, the Singapore based front office trading and technology specialist recruitment company, would like to announce that Nafisa Manasawala will be appointed as Managing Partner of the business from 1st December 2020.

Nafisa has more than 20 years experience in top tier banking as a successful private banker, executive search recruiter and internal talent acquisition specialist. She has worked with banks like Merrill Lynch, Standard Chartered, Credit Suisse and Morgan Stanley. Nafisa combines team management experience with hands-on recruitment experience and deep business understanding, making her a trusted strategic partner in talent management and acquisition.

Nafisa commented, “I am excited to join an established recruitment firm such as Blake Dair Consulting and keen to contribute to the growth of the company through exceptional client service and candidate advisory. My first priority is to build the team selectively, to deepen our experience pool and enhance our market reach.”

“Nafisa joining is fantastic for the team at Blake Dair,” says James Ient, the Founding Shareholder. “The experience Nafisa brings to Blake Dair really helps us achieve our objective of being the preferred employer and preferred vendor in this sector.”

Blake Dair Consulting is a specialist recruitment firm operating in Singapore since 2011 that services clients with roles in Japan, Hong Kong, Malaysia and Singapore in Front Office, Trading and Trading Technology.

+65 67213050

[email protected]

www.bdc.sg

 

Employment Agency License: 11C2852

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News15 mins ago

Putnam Announces Dividend Rates for Open-End Funds

The Trustees of The Putnam Funds have declared the following distributions today.   RECORD PAYMENT FUND NAME AND DISTRIBUTIONS DATE...

gbafNews28 gbafNews28
News18 mins ago

2021 skincare solutions just a click away with POND’S Skin Advisor Live chatbot now on Shopee

Banish Pandemic-induced Skincare Woes with POND’s Beauty Tech on Shopee   HO CHI MINH CITY, VIETNAM – Media OutReach – 1 December...

gbafNews28 gbafNews28
News18 mins ago

Consumer spending in Islamic economy sectors forecast to rebound by end-2021, market size slated to reach US$2.3 trillion by 2024

Takeaways from the State of the Global Islamic Economy Report 2020/21 will be unveiled at Reimagine: Halal in Asia 2020,...

gbafNews28 gbafNews28
News18 mins ago

Infor Launches Hospitality Management Cloud Solution based on Amazon Web Services in China to Spur Digital Transformation among Chinese Hotels

Rich capabilities allow hoteliers to centralize cross-platform hospitality management systems; AWS partnership ensures stability and security of data in the...

gbafNews28 gbafNews28
News18 mins ago

Zipline, Medical Drone Delivery Pioneer to Headline HISA2020

JOHANNESBURG, SOUTH AFRICA – Media OutReach – 30 November 2020 – Technology is transforming industries on a global scale, with the COVID-19 pandemic...

gbafNews28 gbafNews28
News18 mins ago

“Emma by AXA”, your insurance and healthy living partner Download now to enjoy first-in-market free “Post-Vaccination Protection”

HONG KONG SAR – Media OutReach – 30 November 2020 – Emma by AXA — AXA‘s all-in-one insurance & health services platform...

gbafNews28 gbafNews28
News18 mins ago

Lee Kum Kee Sauce Group Appoints Ms. Katty Lam as Chief Executive Officer

HONG KONG SAR – Media OutReach – 1 December 2020 – Lee Kum Kee Sauce Group announces the appointment of Ms. Katty Lam...

gbafNews28 gbafNews28
News18 mins ago

Salaries set to rise in 2021, but employers in the Philippines signal increased caution, says Mercer survey

Companies forecast a 5.6% overall increase in salaries for 2021, but more than half say they expect changes to salary...

gbafNews28 gbafNews28
News18 mins ago

Blake Dair Announces New Managing Partner

SINGAPORE – Media OutReach – 1 December 2020 – Blake Dair Consulting Pte Ltd, the Singapore based front office trading and technology specialist...

gbafNews28 gbafNews28
News18 mins ago

Zane Morton to oversee DHL Global Forwarding in New Zealand and Fiji

The logistics veteran brings four decades of DHL experience to the key role in the South Pacific SINGAPORE – Media OutReach –...